More and more countries are completing their epidemiological mapping of trachoma in suspected
endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of
“trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass... drug
administration (MDA) is normally at the district level and targets the whole population with Zithromax®
tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5
years of age; and tetracycline eye ointment 1% for infants up to 6 months old.
more
Trachoma is the world’s leading infectious cause of blindness. It is one of 18 neglected
tropical diseases (NTDs) that affect over one billion of the world’s poorest people.
The second edition of the Women and Trachoma: Achieving Gender Equity in the Implementation of SAFE manual provides an updated resource for realistically increasing, improving, and supporting gender representation within trachoma elimination efforts at all levels. From the trachoma workforce to the ...patients, from trichiasis surgeons to schoolteachers, and from national to international managers and coordinators, the manual breaks down the various levels of trachoma elimination programming to highlight the areas where women and girls can have a greater impact in elimination effort
more
The WHO Cholera Vaccine Position Paper (August 2017) highlights the importance of oral cholera vaccines (OCVs) as a key tool in outbreak response and prevention, alongside water, sanitation, and hygiene (WASH) measures. It recommends OCVs for high-risk populations, endemic areas, and humanitarian cr...ises, emphasizing their effectiveness in reducing cases and mortality. The paper discusses two types of OCVs (Dukoral®, Shanchol™, Euvichol®) and supports the WHO-managed vaccine stockpile for rapid deployment in cholera-prone regions.
more
Health Services Insights Volume 10: 1–7
Organizing and Delivering High Quality Care for Chronic Noncommunicable Diseases in the Americas
The Integrated Management of Adolescent/Adult Illness (IMAI) approach
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and Local Representatives of regulated products to help in the continuous safety monitoring of products granted marketing authorization in Ghana.
This policy brief aims to provide a review of the current progress on implementing the Burkina Faso national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further progress in the human health sector. The target audience includes all those concerned with implemen...ting actions to combat antimicrobial resistance in Burkina Faso.
more
Evaluation report November 2014